Phase 1 Study of INBRX-105 in Patients With Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma

Conditions:   Metastatic Solid Tumors;   Hodgkin Lymphoma;   Non Hodgkin Lymphoma (NHL);   Non-small Cell Lung Cancer (NSCLC);   Melanoma;   Head and Neck Squamous Cell Carcinoma (HNSCC);   Gastric Adenocarcinoma;   Renal Cell Carcinoma (RCC);   Urothelial Carcinoma;   Esophageal  Adenocarcinoma Intervention:   Drug: INBRX-105 Sponsor:   Inhibrx, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials